Company intelligence / Profile preview

Dialectic Therapeutics, Inc.

Dallas, Texas, United Statesdtsciences.com ↗

Ownership: Private
Development stage: Other

Overview

DT2216, the company’s first-in-class compound using the APTaD™ platform to target BCL family proteins, entered a first-in-human Phase 1 dose escalation trial in patients with relapsed or refractory solid tumors and hematologic malignancies. The compound has received FDA Fast Track designation for PTCL/CTCL and Orphan Drug Designation for T-cell lymphoma. Preclinical data suggest reduced toxicity—especially to platelets—and lower risk of resistance compared to traditional chemotherapy agents.[4][5]

Therapeutic areas: Oncology
Modalities: Targeted protein degraders (specifically antiapoptotic protein targeted degradation)Small molecules (via APTaD™ platform)[4][5]
Industry: Biotech

Drug pipeline

3 assets

DT2216

2 more assets in the full pipeline.

Partnerships

Research partners at UT Health San Antonio and University of Florida Health[4]Supported by Cancer Prevention & Research Institute of Texas grants[2][4]

Beyond the preview

Go deeper on Dialectic Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dialectic Therapeutics, Inc..